TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24911028
Drug: Buspirone titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone titrated to 60 mg/d
Study: 18585835
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 2 g/d for 12 months
Study: 25533307
Drug: Close Rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Close Rectal Dissection (CRD)
Study: 23658423
Drug: 0.45 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45 g/d 20:5n3 and 22:6n3 (1.51:1)
Study: 23658423
Drug: 0.9 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 g/d 20:5n3 and 22:6n3 (1.51:1)
Study: 23658423
Drug: 1.8 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 g/d 20:5n3 and 22:6n3 (1.51:1)
Study: 21874260
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of branched-chain amino acids (BCAA; 12 g/day) and angiotensin-converting enzyme inhibitor (ACE-I; perindopril; 4 mg/day)
Study: 21874260
Drug: ACE-I (perindopril;
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-I (perindopril; 4 mg/day)
Study: 15257378
Drug: Ceftriaxone 2
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 2 g per day for 2 or 3 weeks
Study: 12716812
Drug: Losartan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (100 mg o.d.)
Study: 9988834
Drug: Estrostep (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrostep (20 microg ethinyl estradiol on days 1-5, 30 microg on days 6-12, 35 microg on days 13-21, and 1 mg norethindrone acetate throughout the cycle)
Study: 9988834
Drug: 30-microg ethinyl
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 30-microg ethinyl estradiol monophasic control drug
Study: 9988834
Drug: Triphasic control
Normalized name: Tribasic Calcium Phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic control drug
Study: 7191315
Drug: Acemetacin (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acemetacin (90 mg daily)
Study: 7191315
Drug: Tolmetin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolmetin (600 mg daily)
Study: 31915064
Drug: Morita therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morita therapy
Study: 30203308
Drug: Enhanced version
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced version of parent-implemented Early Start Denver Model (P-ESDM) with motivational interviewing, multimodal learning tools, and weekly 1.5-h home visits for 12 weeks.
Study: 30203308
Drug: Basic model
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic model of parent-implemented Early Start Denver Model (P-ESDM) with 1.5 h of clinic-based parent coaching weekly for 12 weeks.
Study: 25156040
Drug: Low-dose beta-carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose beta-carotene (10 mg day(-1)) and vitamin C (500 mg day(-1))
Study: 25156040
Drug: Placebo (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (50 mg day(-1) of vitamin C)
Study: 25156040
Drug: Low-dose beta-carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose beta-carotene and vitamin C
Study: 11352955
Drug: HD-MVAC (high-dose-intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD-MVAC (high-dose-intensity chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin plus granulocyte colony-stimulating factor)
Study: 11352955
Drug: MVAC (classic
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVAC (classic chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin)
Study: 8004882
Drug: Nisoldipine and
Normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nisoldipine and Propranolol (10 mg twice daily and 80 mg twice daily respectively)
Study: 23097272
Drug: Iron (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron (50 mg) plus DHA/EPA (420/80 mg)
Study: 16960468
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg dapoxetine and 20 mg paroxetine
Study: 9425966
Drug: Subarachnoid lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subarachnoid lidocaine (75 mg)
Study: 9425966
Drug: Subarachnoid lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subarachnoid lidocaine (75 mg) in women
Study: 27639604
Drug: Cabergoline 0.5mg
Normalized name: CABERGOLINE 0.5MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline 0.5mg weekly for three months
Study: 20067426
Drug: Anthelminthic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthelminthic treatment
Study: 18717802
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 microg x kg(‐1) over 20 min followed by an infusion of 0.5 microg x kg(‐1) x h(‐1)) as an adjunct to TIVA (propofol and remifentanil)
Study: 18717802
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 microg x kg(‐1) over 20 min followed by an infusion of 0.5 microg x kg(‐1) x h(‐1))
Study: 10343216
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg hyoscyamine sulfate intravenous (n = 57)
Study: 22146757
Drug: Upstream use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upstream use of clotinab with 600-mg clopidogrel pretreatment
Study: 22146757
Drug: Provisional use
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provisional use of clotinab with 600-mg clopidogrel pretreatment
Study: 20648601
Drug: Overlap of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overlap of LAM and ADV for 3 months followed by ADV monotherapy
Study: 17466071
Drug: Topical honey
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical honey along with intralesional injection of glucantime
Study: 17466071
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of glucantime alone
Study: 14964629
Drug: Pimecrolimus cream
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimecrolimus cream 1% applied twice daily with overnight occlusion
Study: 11313170
Drug: L-758,298 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-758,298 (60 or 100 mg)
Study: 11313170
Drug: Ondansetron (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (32 mg)
Study: 8198929
Drug: Locally applied
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Locally applied morphine at 100 ng ml‐1
Study: 8198929
Drug: Locally applied
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Locally applied morphine at 100 micrograms ml‐1
Study: 3332675
Drug: Acyclovir 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 3% ointment and vidarabine 3% ointment
Study: 3332675
Drug: Acyclovir 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 3% ointment and placebo
Study: 22666758
Drug: Injection (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection (control group)
Study: 19913781
Drug: Online cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online cognitive behavioral therapy (CBT)
Study: 19913781
Drug: Online problem-solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online problem-solving therapy (PST)
Study: 16364838
Drug: Spironolactone 50
Normalized name: spironolactone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 50 mg/day
Study: 16364838
Drug: Bendroflumethiazide 2.5
Normalized name: bendroflumethiazide 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendroflumethiazide 2.5 mg/day
Study: 16364838
Drug: Spironolactone 50
Normalized name: spironolactone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 50 mg/day (for resistant hypertension)
Study: 11850256
Drug: Caspofungin 5
Normalized name: caspofungin 50 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin 5 to 100 mg (single-dose)
Study: 11850256
Drug: Caspofungin 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin 15 mg daily (multiple-dose)
Study: 11850256
Drug: Caspofungin 50
Normalized name: caspofungin 50 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin 50 mg daily (multiple-dose)
Study: 11850256
Drug: Caspofungin 70
Normalized name: caspofungin 70 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin 70 mg daily (multiple-dose)
Study: 11850256
Drug: Caspofungin 50
Normalized name: caspofungin 50 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin 50 mg daily without loading dose (multiple-dose)
Study: 11850256
Drug: Caspofungin 70
Normalized name: caspofungin 70 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin 70 mg daily (3-week study)
Study: 8572837
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of losartan potassium and 12.5 mg of hydrochlorothiazide
Study: 1956528
Drug: Carbohydrate-electrolyte solution
Normalized name: CARBOHYDRATE/ELECTROLYTES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-electrolyte solution 2 (CE2)
Study: 1956528
Drug: Carbohydrate-electrolyte solution
Normalized name: CARBOHYDRATE/ELECTROLYTES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-electrolyte solution 1 (CE1)
Study: 6129886
Drug: Non-selective beta-adrenoceptor
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-selective beta-adrenoceptor blocker propranolol
Study: 6129886
Drug: Selective beta-adrenoceptor
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective beta-adrenoceptor blocker metoprolol
Study: 26049533
Drug: Electronic interactive
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic interactive tablet intervention
Study: 22031171
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 or 20 mg/day depending on weight)
Study: 19539430
Drug: Platinum chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum chemotherapy regimens
Study: 19539430
Drug: Taxane chemotherapy
Normalized name: acetaminophen / oxycodone hydrochloride Oral Capsule [Taxadone]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxane chemotherapy regimens
Study: 19539430
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of platinum and taxane chemotherapy regimens
Study: 19539430
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with an agent other than platinum or taxane
Study: 14678347
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (1200 microg)
Study: 12231083
Drug: Furosemide 40
Normalized name: furosemide 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 40 mg once daily
Study: 12231083
Drug: Captopril 6.25
Normalized name: captopril 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 6.25 mg twice daily
Study: 12231083
Drug: Furosemide 40
Normalized name: furosemide 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 40 mg once daily (2-week treatment)
Study: 12231083
Drug: Captopril 12.5
Normalized name: captopril 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 12.5 mg twice daily (2-week treatment)
Study: 8008342
Drug: 5-Fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-Fluorouracil (5-FU) injections (5 mg, five injections over 2 weeks post-surgery)
Study: 8008342
Drug: 5-Fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-Fluorouracil (5-FU) injections
Study: 8008342
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no injections)
Study: 24549160
Drug: Tiotropium bromide
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiotropium bromide (18 μg) once daily inhaled capsule
Study: 21986341
Drug: Cognitive rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive rehabilitation (CR) intervention comprising 12 individual weekly sessions
Study: 18574929
Drug: Therapy for
Normalized name: nutritional therapy for GSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy for early stage patients
Study: 18574929
Drug: Antiparkinsonian therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiparkinsonian therapy for late stage patients
Study: 15160570
Drug: Topical placental
Normalized name: human placental tissue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical placental extract
Study: 11219875
Drug: Conventional analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional analgesic management
Study: 29952641
Drug: Midazolam (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.04 mg/kg) with propofol
Study: 21163585
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser (LLL) therapy 2.5 J/cm(2)
Study: 15356829
Drug: Amprenavir-ritonavir (APV-RTV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amprenavir-ritonavir (APV-RTV) 600/100 mg b.i.d.
Study: 15356829
Drug: Amprenavir-ritonavir (APV-RTV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amprenavir-ritonavir (APV-RTV) 1200/200 mg q.d.
Study: 15356829
Drug: Both regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both regimens (APV-RTV 600/100 mg b.i.d. and APV-RTV 1200/200 mg q.d.)
Study: 9926292
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 5g daily for 4 weeks
Study: 9926292
Drug: Antacids for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacids for 4 weeks (Control)
Study: 2831525
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of enalapril
Study: 2831525
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of enalapril (after dosage increase)
Study: 2831525
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of atenolol (after dosage increase)
Study: 31990730
Drug: Gum chewing
Normalized name: Nicotine (as nicotine polacrilex) 4 mg oral gum chewing gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gum chewing for 2 minutes before induction of anesthesia (group G)
Study: 31990730
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (group C) asked to swallow twice without additional treatment
Study: 31990730
Drug: Gum chewing
Normalized name: Nicotine (as nicotine polacrilex) 4 mg oral gum chewing gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gum chewing (group G)
Study: 31990730
Drug: Gum chewing
Normalized name: Nicotine (as nicotine polacrilex) 4 mg oral gum chewing gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gum chewing (group G) in patients with bloody SGA devices
Study: 31990730
Drug: Gum chewing
Normalized name: Nicotine (as nicotine polacrilex) 4 mg oral gum chewing gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gum chewing (group G) in patients without bloody SGA devices
Study: 29358539
Drug: 625 mg
Normalized name: betaine 625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 625 mg of combined amoxicillin and clavulanic acid tablet
Study: 29358539
Drug: 625 mg
Normalized name: betaine 625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 625 mg of combined amoxicillin and clavulanic acid tablet + 400 mg metronidazole tablet
Study: 18412944
Drug: Real rTMS
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real rTMS treatment (1 Hz for 2 weeks)
Study: 16485876
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with topical 5‐aminolevulinic acid (ALA), treated 4 times weekly with 30‐minute ALA incubation and blue light activation.
Study: 16485876
Drug: Topical clindamycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clindamycin, used as control treatment.
Study: 10426835
Drug: Ambulatory intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulatory intermittent dobutamine infusion at 2.5 microgram/kg/min for 48 hours/week for 6 months
Study: 10426835
Drug: Optimal standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal standard treatment (control group)
Study: 9136493
Drug: Methylphenidate 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 0.1 mg/kg
Study: 7372783
Drug: Intravenous beta-endorphin
Normalized name: beta-endorphin human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous beta-endorphin infusion
Study: 26353829
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D supplementation (1,600 IU/day for <1 year old, 2,400 IU/day for >1 year old)
Study: 23368915
Drug: ω‐3 polyunsaturated
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 polyunsaturated fatty acids (PUFAs) supplemented parenteral nutrition (PN)
Study: 23368915
Drug: Isocaloric and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric and isonitrogenous parenteral nutrition (PN) without ω‐3 PUFAs
Study: 21269649
Drug: Mitral valve
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitral valve surgery with implantation of the CorCap cardiac support device (treatment group)
Study: 19149978
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg/day for 6 weeks) followed by Ivermectin (150 microg/kg orally)
Study: 11208636
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 500 microg twice daily
Study: 9033439
Drug: Salmeterol 21
Normalized name: SALMETEROL 21MCG 60D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 21 micrograms twice daily
Study: 8331545
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of APD over 4 h
Study: 8331545
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of APD over 24 h
Study: 16237386
Drug: estradiol (Estrofem;
Approvals — FDA: no, EMA: no, PMDA: no
Description: estradiol (Estrofem; 2 mg)
Study: 16237386
Drug: buspirone (Buspar;
Approvals — FDA: no, EMA: no, PMDA: no
Description: buspirone (Buspar; 5 mg)
Study: 15504379
Drug: Medical abortion
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical abortion (600 mg mifepristone and 1 mg gemeprost)
Study: 10843450
Drug: Prazosin 0.5
Normalized name: prazosin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin 0.5 mg twice daily
Study: 10843450
Drug: Terazosin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin 0.5 mg twice daily
Study: 10843450
Drug: Tamsulosin 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.1 mg once daily
Study: 3100464
Drug: Oral prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prostaglandin E1 (PGE1) analogue
Study: 2839813
Drug: Rhesus rotavirus
Normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhesus rotavirus vaccine MMU 18006 (10^5, 10^4, or 10^3 plaque-forming units)
Study: 2839813
Drug: Rhesus rotavirus
Normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhesus rotavirus vaccine MMU 18006
Study: 14558397
Drug: Topical 20%
Normalized name: urea topical 20% topical foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 20% 5-aminolevulinic acid (5-ALA) followed by 595 nm pulsed dye laser (PDL) irradiation
Study: 14558397
Drug: Pulsed dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed dye laser (PDL) treatment alone or untreated lesions
Study: 3804884
Drug: Ceftriaxone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (1 g intravenously every 12 h for mean duration 8.7 days)
Study: 3804884
Drug: Cefamandole (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole (1.5 g intravenously every 6 h for mean duration 8.2 days)
Study: 30839013
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO, n = 35, 2 g day‐1 eicosapentaenoic acid + docosahexaenoic acid)
Study: 30839013
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil (FLO, n = 39, 2.5 g day‐1 α‐linolenic acid)
Study: 28335886
Drug: OxCapRT (oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: OxCapRT (oxaliplatin 85 mg/m2 day 1, 15, 29; capecitabine 625 mg/m2 bd on days of radiotherapy)
Study: 28335886
Drug: CarPacRT (carboplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CarPacRT (carboplatin AUC2; paclitaxel 50 mg/m2 day 1, 8, 15, 22, 29)
Study: 24595578
Drug: Ivermectin 1%
Normalized name: IVERMECTIN 1% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin 1% cream
Study: 19208350
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg/day for 1 month (increased to 40 mg/day at day 15)
Study: 19208350
Drug: Simvastatin with
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin with beta-adrenergic blockers
Study: 19208350
Drug: Simvastatin without
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin without beta-adrenergic blockers
Study: 9469328
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA) 160 mg